KRT17 Promotes Endometrial Cancer Cell Migration and Angiogenesis by Regulating HIF-1α/VEGF Pathway

    January 2023 in “ European journal of gynaecological oncology ”
    Liyan Xu, Yanbo Liu, Ping Xu, Limei Zhang, Mo Li, Yang Zhang, Ping Lü, Fengxia Xue
    Image of study
    TLDR KRT17 may be a new target for endometrial cancer treatment because it helps cancer cells move and form new blood vessels.
    KRT17, a protein known for its role in hair formation, was found to be highly expressed in human endometrial cancer (EC) cells. The study demonstrated that removing KRT17 not only suppressed EC cell growth but also reduced cell motility and inhibited angiogenesis, which is crucial for tumor growth and metastasis. The research further revealed that KRT17 influences EC progression by regulating the HIF-1α/VEGF pathway, as evidenced by tumor growth assays in mice. These findings suggest that KRT17 may be a potential therapeutic target for treating endometrial cancer.
    Discuss this study in the Community →